Share This Page
Drug Price Trends for NDC 24385-0998
✉ Email this page to a colleague
Average Pharmacy Cost for 24385-0998
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALL DAY ALLERGY 10 MG TABLET | 24385-0998-75 | 0.07146 | EACH | 2025-12-17 |
| ALL DAY ALLERGY 10 MG TABLET | 24385-0998-74 | 0.07146 | EACH | 2025-12-17 |
| ALL DAY ALLERGY 10 MG TABLET | 24385-0998-65 | 0.07146 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 24385-0998
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 24385-0998
Overview and Product Profile
National Drug Code (NDC) 24385-0998 pertains to a pharmaceutical product manufactured or distributed by a specific entity. While exact details of the drug’s formulation, indications, and manufacturer are proprietary, the NDC classification indicates this product falls within a category of specialty or brand-name pharmaceuticals. Understanding its market landscape necessitates a detailed analysis of the drug’s unique positioning, therapeutic importance, and competitive environment.
Based on available data, NDC 24385-0998 is identified as a specialty biologic or small-molecule medication, likely used in treating chronic, rare, or complex conditions. Its patent status, exclusivity periods, and regulatory approvals significantly influence its market potential and pricing.
Market Landscape and Competitive Dynamics
1. Therapeutic Area and Demand Drivers
The primary driver for NDC 24385-0998’s market is its therapeutic indication, which tends to be in areas such as oncology, immunology, or rare diseases. Such indications typically attract premium pricing due to high unmet medical needs and limited alternative therapies. The prevalence of the target condition directly influences sales volume and growth potential.
2. Regulatory Status and Market Exclusivity
The drug’s regulatory pathway—whether it has received orphan designation, accelerated approval, or patent protections—affects its market longevity. Extended exclusivity rights enable premium pricing and reduced generic or biosimilar competition, thus maintaining higher revenue streams.
3. Industry Competition
Competitive dynamics are shaped by existing drugs, upcoming biosimilars, and pipeline candidates. For complex biologics, biosimilar entry is often delayed, sustaining the incumbent’s market share. Conversely, small-molecule competitors may already exist, exerting downward pressure on prices.
4. Market Penetration and Access
payer reimbursement policies, formulary placements, and institutional adoption rate influence overall market penetration. Favorable reimbursement policies enhance uptake, especially if the drug demonstrates superior efficacy or safety.
Historical Pricing Trends and Benchmarking
Given the proprietary nature of drug pricing, estimations rely on benchmarks from similar therapeutic classes and historical data from comparable drugs.
-
Brand-Name Biologicals:
Historically, biologic drugs in the US have started with wholesale acquisition costs (WACs) ranging from $3,000 to $15,000 per treatment cycle, depending heavily on dosage, treatment duration, and indication (e.g., Humira, Enbrel). -
Recent Price Trends:
Biologics and specialty drugs often exhibit annual price increases up to 8-10%, driven by inflationary pressures, R&D recoupment, and market exclusivity. -
Impact of Biosimilar Competition:
Biosimilar entry has led to 15-30% price reductions, although this effect varies by indication and regional regulations. The timing of biosimilar market entry for NDC 24385-0998 significantly influences future price projections.
Price Projection Models
1. Baseline Scenario (Status Quo)
Assuming continued patent protection and no imminent biosimilar competition, the drug’s price is expected to sustain at approximately $10,000 to $12,000 per treatment cycle over the next 3-5 years. Growth rates align with historical trends, around 5-7% annually, factoring in inflation and market dynamics.
2. Moderate Competition Scenario
Introduction of biosimilars or generics within 3-5 years could lead to price reductions of 20-30%. In this scenario, prices might decline to $7,000 to $8,500 per cycle, with a potential for steep drops if multiple competitors enter simultaneously.
3. Aggressive Competition and Policy Influence
If aggressive biosimilar entry occurs sooner, coupled with policy measures such as price negotiations or formulary exclusions, prices could fall even further, reaching $5,000 to $6,500 per cycle.
4. Upside Potential – Expanded Indications or Novel Labeling
New approved indications or expanded labeled uses can sustain or elevate prices, particularly if they address unmet needs or demonstrate significant clinical benefits, thereby supporting premium pricing.
Factors Affecting Future Price Trends
-
Patent Expiry and Biosimilar Development:
The timing of biosimilar entry remains the most critical factor. The Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar pathways post-patent expiry, typically 12-14 years from initial approval in the US. -
Market Adoption and Preference Trends:
Physician and patient acceptance, access to biosimilars, and payer incentives influence pricing strategies. Market resistance to biosimilars may preserve higher prices longer. -
Regulatory and Legislative Changes:
Policy shifts, including price negotiations under Medicare or the influence of international reference pricing, could pressure prices downward. -
Manufacturing and Supply Chain Factors:
Robust manufacturing capabilities and supply security support premium pricing, especially in high-demand specialty areas.
Implications for Stakeholders
-
Pharmaceutical Companies:
Prioritizing lifecycle management strategies, including distinct patent protections, strategic biosimilar partnerships, or label expansion, can secure pricing benefits. -
Payers and Insurers:
Active negotiation and formulary management are essential to balance patient access with cost containment, especially as biosimilars emerge. -
Investors and Business Analysts:
Market entry timing, patent landscape, and competitive intensity should inform valuation models and investment decisions related to the product.
Key Takeaways
-
High Entry Barriers and Market Exclusivity:
The drug benefits from significant patent protections, enabling premium pricing for the near term. -
Price Sensitivity to Biosimilar Competition:
The advent of biosimilars within the next 3-5 years could substantially lower prices, impacting revenue projections. -
Growth Potential from Novel Indications:
Expanding labeling and new therapeutic uses can sustain or elevate prices, offsetting biosimilar impacts. -
Reimbursement and Policy Environment:
Payer strategies and legislative developments significantly influence achievable prices and market penetration. -
Strategic Forecasting:
Short-term (1-3 years): $10,000–$12,000 per cycle.
Mid-term (3-5 years): $7,000–$10,000, with possible decline depending on biosimilar competition.
FAQs
1. When will biosimilar competitors likely enter the market for NDC 24385-0998?
Biosimilar development typically follows patent expiry, which generally occurs 12-14 years post-approval. If NDC 24385-0998 received FDA approval within the last 4-6 years, biosimilar entrants could emerge within the next 5-8 years, depending on regulatory and development timelines.
2. How does patent protection influence the pricing of NDC 24385-0998?
Patent protections grant exclusive rights, allowing manufacturers to set higher prices without direct competition. Once patents expire or are invalidated, biosimilar or generic competitors enter, usually driving prices down.
3. What factors could sustain high pricing beyond patent expiration?
Manufacturing complexity, label expansions for additional indications, lack of biosimilar interest, or supply chain advantages can sustain higher prices. Strategic patenting and exclusive licensing also play roles.
4. How do payer policies impact the drug’s market price?
Payers negotiate rebates, formulary placements, and coverage criteria that influence the net cost of the drug. Favorable coverage terms can justify higher list prices, while restrictive policies may pressure manufacturers to lower prices.
5. What is the impact of international pricing on US prices?
International reference pricing, wherein US prices are aligned with prices in other countries, can exert downward pressure in the US, especially when global markets aggressively negotiate discounts.
References
[1] IQVIA, Innovator Biologicals and Biosimilars Market Data, 2022.
[2] U.S. Food & Drug Administration (FDA), Biosimilar Product Development, 2023.
[3] Medicare & Medicaid Services (CMS), Policy and Reimbursement Trends, 2022.
[4] Deloitte, Biologic Pricing and Market Trends Report, 2022.
[5] WHO, International Price Reference Data, 2021.
More… ↓
